Manifold learning (ML) comprehends a set of nonlinear techniques for mining and representing high-dimensional data. In this work, we approach the well-known and successful ML technique called Riemannian Manifold Learning (RML). Firstly, we present a geometric interpretation of the main steps of selecting visible and safe neighborhoods to reconstruct geometry and topology in the original RML algorithm. Then, we describe and implement a new method of selecting safe neighbors for this algorithm. Our experimental results on synthetic and real data sets, using open source tools and a public face image database, have showed that the new method proposed shows similar results to the original one and reconstructions that favour local rather than holistic similarities described by the data. Additionally, since the new method proposed requires the specification of only one input parameter, its implementation is simpler and more intuitive than the original one.

2018-10-01·Journal of Lightwave Technology

Integration of a GFDM-Based 5G Transceiver in a GPON Using Radio Over Fiber Technology

作者: Hugo Rodrigues Dias Filgueiras ; Matheus Seda Borsato Cunha ; Danilo Henrique Spadoti ; Arismar Cerqueira Sodre ; Regivan N. da Silva ; Igor Feliciano da Costa ; Tiago Reis Rufino Marins ; Ramon Maia Borges ; Luciano Leonel Mendes

This paper reports the integration and experimental performance analysis of a GFDM-based 5G transceiver in a gigabit passive optical network (GPON), using radio over fiber technology. The proposed architecture enables to simultaneously transport two 5G candidates RF signals through an active GPON under real channel conditions. One signal is generated by a GFDM-based 5G prototype transceiver at 735 MHz, whereas the second one is synthetized by a vector signal generator at 26 GHz. A dual-drive Mach–Zehnder modulator has been utilized in the optical line terminal to modulate both signals, with the purpose of mitigating the interference between them. Particularly for the GFDM-based 735 MHz signal, a modulation error ratio (MER) of 40 dB has been obtained at RF-driven signal up to –9 dBm. Furthermore, the use of a digital predistortion scheme has been efficiently employed to reduce the impact of the nonlinear distortions and enhance MER. The 26-GHz RF signal, aimed for the 5G millimeter wave band, has been investigated as a function of error vector magnitude (EVM) for bitrates up to 1 Gbit/s. ${\text{EVM}}_{{\text{RMS}}}$ of 2.18% and 5.70% have been obtained for 100 Mbit/s and 1 Gbit/s, respectively. Finally, the latency and throughput measurements of the baseband signal originally running over GPON have shown no significant penalties.

2018-08-01·Acta Materialia

Discerning interface atomistic structure by phase contrast in STEM: The equilibrated Ni-YSZ interface

作者: Doron Shilo ; Hadar Nahor ; Yaron Kauffmann ; Wayne D. Kaplan ; Sorin Lazar

Equilibrated interfaces between Ni and yttrium stabilized zirconia (YSZ) were formed by solid-state dewetting of thin Ni films on the (111) surface of YSZ single crystals at 1350°C and an oxygen partial pressure of P(O₂)=10^-20 atm.The atomistic structure of the equilibrated solid-solid Ni[1̅10]111‖YSZ[11̅0]111 interface was determined by monochromated and aberration-corrected scanning transmission electron microscopy, using different techniques.It was found that due to the large lattice mismatch between Ni and YSZ the interface reconstructs, and adopts a unique structure which consists of a high d. of misfit dislocations.However, despite the large lattice mismatch, this interface is not incoherent.The interface was confirmed to be cation terminated, which is probably due to the low oxygen partial pressure used to reach equilibrium

项与 FEI Co. 相关的新闻（医药）

2024-06-19

·生物制药小编

直播预告 | 深入探索 QSP 如何加速双特异性抗体药物开发进程

目前有 50 多种双特异性抗体正处于肿瘤学临床开发阶段，其形式多种多样，针对一系列免疫和肿瘤靶点。双特异性抗体已证明具有提高疗效和降低全身毒性的潜力。然而，双特异性抗体是一种复杂的治疗方式，在早期临床试验中需要克服诸多挑战，包括选择相关的起始剂量和剂量递增策略，这是因为暴露-效应关系并不直观;此外，细胞因子释放综合征（cytokine-release syndrome, CRS）的预测和管理也很重要。从临床前研究向临床研究的转化需要考虑多重因素，包括肿瘤生长速度、两个靶点的受体表达、靶点结合亲和力、效应细胞与靶细胞的比例、可溶性靶点的存在以及 PK 差异。机制性的定量系统药理学（quantitative systems pharmacology，QSP）模型正越来越多地用于双特异性药物的设计以及指导转化研究、临床试验设计、剂量方案优化和患者选择。本次网络讲座将介绍双特异性抗体在肿瘤治疗中的潜力和挑战，并介绍了如何利用 QSP 模型等工具来克服这些挑战，推动双特异性抗体在肿瘤临床开发中的进一步发展。网络研讨会对谁最有帮助：对如何利用 QSP 模型设计新型双特异性抗体药物以及优化现有双特异性抗体药物的发现和开发感兴趣的制药公司科学家。直播时间： 2024 年 6 月 25 日 19:00 - 20:00 报名方式：点击此处或扫描下方二维码报名讲师 Fei Hua, PhD 建模与模拟业务副总裁，Applied BioMath（Part of Certara） Fei Hua, PhD 是 Applied BioMath（2023年被Certara收购）建模与模拟业务副总裁。主要负责与潜在客户合作，确定项目范围，并指导从早期发现到临床开发的客户项目，确保及时交付高质量的建模与模拟结果，以解决关键问题。在加入 Applied BioMath 之前，Fei 曾在辉瑞公司担任临床药理学总监。Fei 在清华大学获得生物科学学士学位，在康奈尔大学生理学系获得博士学位，随后在麻省理工学院生物医学工程系接受博士后培训。Fei 在建模与模拟领域拥有 20 多年的经验，曾在药物研发的不同阶段为肿瘤学、CVMED、免疫学、神经科学和罕见病等多个不同疾病领域的项目提供支持。Fei在如何通过建模与模拟实现数据整合和生理学理解，从而帮助解答药物开发项目中的关键问题以及节约成本和时间方面具有第一手经验。问答环节 Certara中国区首席科学官兼全球综合药物开发部高级副总裁李改玲博士将在线参与答疑解惑。

并购

2023-10-19

·BioSpace

Syncell Appoints Life Science Industry Leaders Dr. Martin Madaus and Dr. Don Kania as Business Strategic Advisors

Dr. Martin Madaus and Dr. Don Kania are recognized for their significant contributions to the field of life science technology and bring over 50 years of combined experience to the Syncell team. The new Business Strategic Advisors will use their long-standing expertise to drive the company's growth and innovation in spatial proteomics. TAIPEI, Taiwan & LOS ALTOS, Calif.--(BUSINESS WIRE)-- Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company. With their extensive backgrounds in the life science industry, both Dr. Madaus and Dr. Kania will guide Syncell's growth and innovation, helping the company become a major player in the spatial proteomics industry. Dr. Madaus brings over 30 years of experience in the biotechnology, diagnostics, and pharmaceutical sectors. He is a transformative leader guiding the growth of many companies, currently serving as Chairman of Quanterix, Senior Healthcare Operating Executive of the Carlyle Group, and a Board Member of multiple high-pro companies. His distinguished career includes serving as President, Chairman, and CEO of Millipore, President and CEO of Roche Diagnostics North America, and Chairman and CEO of Ortho-Clinical Diagnostics. Dr. Madaus shared enthusiasm about his new role: “Syncell is pushing the boundaries of spatial proteomics with its innovative Microscoop technology. This platform improves our ability to study the functions and interactions of proteins, which is key to understanding the underlying mechanisms of diseases and identifying new drug targets. I am excited to join Syncell as a Business Strategic Advisor and contribute to their mission to advance the field of proteomics with this novel platform." Dr. Kania is also a seasoned leader in the field, bringing over 25 years of experience in the life science technology, biotechnology, and photonics industries. He is Chairman of Gandeeva Therapeutics and a Board Member of Intuitive Surgical, Lumicks, and several other startup companies. He is best recognized for his role as CEO and President of FEI Company, which he built to become a global leader in cryo-electron microscopy, a game-changing structural biology technology. Dr. Kania commented: “Syncell’s Microscoop technology will contribute to a new era of biological discoveries that could accelerate the development of potentially life-saving drugs. I am honored to be a part of the Syncell team and look forward to helping guide the company's expansion, enabling more researchers access to this groundbreaking tool.” Syncell founder and CEO, Jung-Chi Liao, expressed excitement about the appointment of the new Business Strategic Advisors, stating, "We are thrilled to welcome Dr. Martin Madaus and Dr. Don Kania to the Syncell family. Their vast experience and precision leadership in the life science technology sector will undoubtedly elevate our company to new heights, and we look forward to their invaluable contributions." As strategic business advisors, Dr. Madaus and Dr. Kania will provide guidance and collaborate with Syncell on various aspects of its operations, including business strategy, commercialization planning, product development, and fundraising efforts. About Syncell Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial biomarker discovery feasible for the first time. This spatial proteomics technology is applicable to a broad scope of biological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. Learn more at View source version on businesswire.com: Contacts Jennie Wu JennieWu@syncell.com Source: Syncell View this news release online at:

高管变更

2023-02-27

·Business Wire

ONI Appoints Paul Scagnetti as CEO to Implement Next Chapter of Growth

OXFORD, England & SAN DIEGO--( BUSINESS WIRE )--ONI, the biotechnology company broadly enabling the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced that Paul Scagnetti has been appointed as the company's new CEO, effective February 27, 2023. Along with this leadership change, ONI will begin to implement a new strategy to accelerate commercial growth and expand its impact in research and discovery. Paul succeeds founding CEO, Bo Jing, who will remain with ONI as a key contributor in product development to help inspire ONI’s next innovations. Paul brings over 25 years of experience in the life science and technology markets and comes with a proven track of success for both large and small companies. Prior to joining ONI, Paul’s most recent role was Vice President of Corporate and Business Development at Illumina, where he led M&A, partnerships, and licensing. Paul’s experience spans international leadership roles where his responsibilities ranged from general management, new business development, and strategic planning at companies such as FEI and Intel. “This is a great time to be joining ONI! The Nanoimager that the ONI team has developed is a breakthrough in expanding the use of microscopy in life sciences. It’s going to be increasingly important for researchers who want to connect multi-omic analysis to a wide range of biological phenomena that can only be seen with super resolution microscopes. The microscopy and data analysis platforms will form a strong basis for us to grow the company and add tremendous value to life scientists,” said incoming CEO Paul Scagnetti. As CEO, Paul will be responsible for driving the company's future growth and expanding its reach to new customers and markets. He will also build on ONI’s vision to enable better science through delivering accessible and innovative new technologies to scientists around the world. “Paul's experience in building businesses, in particular in the microscopy arena, will help drive ONI's mission to truly democratize super resolution imaging. We are pleased to have him on board and look forward to seeing him realize the potential of this company,” said Patrick Finn, Ph.D., chairman of the board of ONI. About ONI ONI’s mission is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand, and share the microscopic details of life. ONI’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualizing and tracking individual molecules in complex systems such as nanoparticles, living cells, and tissue with 20 nm resolution. ONI has continued this trend of democratizing super-resolution microscopy through the introduction of CODI, a software platform for acquisition, analysis, collaboration, and storage of super-resolution data. ONI was founded as a spin-out from Oxford University and has rapidly grown since its inception with offices now in San Diego, CA (HQ) and Oxford, UK. For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI www.oni.bio

高管变更

100 项与 FEI Co. 相关的药物交易

登录后查看更多信息

100 项与 FEI Co. 相关的转化医学

登录后查看更多信息